Greaney

Margaret Theresa Greaney, County Kerry IE

Patent application number	Description	Published
20100286020	MILK PROTEIN COMPOSITION AND USE THEREOF - A milk protein composition for use in treating or preventing chronic local inflammation in humans is disclosed. The invention also relates to the use of the milk protein composition for the manufacture of a nutritional composition and/or pharmaceutical composition for use in treating or preventing chronic local inflammation in humans. A nutritional composition, a pharmaceutical composition and a daily diet for treating or preventing chronic local inflammation in humans are also disclosed.	11-11-2010

Patent application number	Description	Published
20110293443	INFUSION PUMP WITH MULTIPLE ORIENTATION DISPLAY - An infusion pump including a pump actuator; a fluid assembly operable with the pump actuator, the fluid assembly including an outlet line; a housing configured at its front side to receive the fluid assembly and at its backside to mount in either a first orientation or a second orientation to an external support, wherein the housing supports the pump actuator and the fluid assembly in each of the orientations, and wherein the outlet line extends from a surface of the housing; a controller operably connected to the housing; and a display operably connected to the controller and supported by the front side of the housing, the display configured to be rotatable responsive so that information displayed by the display is oriented right-side-up regardless of whether the surface from which the output extends is in the first orientation or the second orientation.	12-01-2011

Patent application number	Description	Published
20080241109	Method for Ex-Vivo Purging in Autologous Transplantation - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address.	10-02-2008